Also trades as: 4502.T (JPX) · $vol 168M · TKPHF (OTC) · $vol 0M

$20.27

-0.16 (-0.78%)

After Hours: $20.23 (-0.04, -0.22%)

Weekly Expected Move ±3.0%

$19 $20 $20 $21 $21

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Strong Buy · Power 72 · $65.0B mcap · 3.16B float · 0.094% daily turnover · Short 29% of daily vol

Credit Risk of going bust: lower than 78% of companies Debt: 32.5% of company value Bonds: $208.5M held by 194 funds, 85 bp over Treasuries → details ▾

If the stock fell to about $0.49 (down 98%), Takeda Pharmaceutical Company Limited would be worth roughly what it owes.
Total debt $31.37B against a stock market value of $65.02B.
Distance to default 9.16 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $17.34B (short-term plus half of long-term), stock volatility 21.6%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions ETF Exposure Dark Pool Short Interest

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$4.58T +7.5% ▲

5Y CAGR: +6.8%

Gross Profit

$3.00T +6.0% ▲

5Y CAGR: +6.4%

Operating Income

$342.6B +60.0% ▲

5Y CAGR: +27.8%

Net Income

$107.9B -25.1% ▼

5Y CAGR: +19.5%

EPS (Diluted)

$33.62 -26.3% ▼

5Y CAGR: +18.9%

EBITDA

$1.21T +5.8% ▲

5Y CAGR: +12.5%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2020	FY2021	FY2022	FY2023	FY2024
Revenue	$3.20T	$3.57T	$4.03T	$4.26T	$4.58T
YoY Growth	-2.8%	+11.6%	+12.8%	+5.9%	+7.5%
Cost of Revenue	$994.3B	$1.11T	$1.24T	$1.43T	$1.58T
Gross Profit	$2.20T	$2.46T	$2.78T	$2.83T	$3.00T
Gross Margin	68.9%	69.0%	69.1%	66.4%	65.5%
R&D Expenses	$455.8B	$526.1B	$633.3B	$729.9B	$730.2B
SG&A Expenses	$875.7B	$886.4B	$997.3B	$1.05T	$1.10T
Operating Expenses	$1.69T	$2.00T	$2.29T	$2.62T	$2.66T
Operating Income	$509.3B	$460.8B	$490.5B	$214.1B	$342.6B
Operating Margin	15.9%	12.9%	12.2%	5.0%	7.5%
Interest Expense	$130.8B	$122.4B	$117.0B	$1.1B	$137.3B
Income Before Tax	$366.2B	$302.6B	$375.1B	$52.8B	$175.1B
Tax Expense	-$9.9B	$72.4B	$58.1B	-$91.4B	$66.9B
Net Income	$376.0B	$230.1B	$317.0B	$144.1B	$107.9B
Net Margin	11.8%	6.4%	7.9%	3.4%	2.4%
EPS (Diluted)	$119.48	$72.94	$100.97	$45.58	$33.62
EBITDA	$983.7B	$1.18T	$1.28T	$1.14T	$1.21T
Shares Outstanding	3.15B	3.15B	3.14B	3.16B	3.21B

Line Item	FY2024 Q2	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1
Revenue	$1.18T	$1.14T	$1.05T	$1.11T	$1.11T	$1.21T	$1.11T	$1.22T
Cost of Revenue	$394.3B	$416.9B	$382.1B	$384.7B	$380.1B	$552.9B	$570.8B	$406.7B
Gross Profit	$781.7B	$727.2B	$671.3B	$722.0B	$732.7B	$660.3B	$543.8B	$813.2B
Gross Margin	66.5%	63.6%	63.7%	65.2%	65.8%	54.4%	48.8%	66.7%
R&D Expenses	$175.6B	$170.2B	$216.0B	$143.9B	$161.5B	$178.4B	$198.9B	$167.4B
SG&A Expenses	$268.3B	$270.6B	$295.9B	$255.9B	$253.6B	$287.9B	$297.4B	$286.5B
Operating Expenses	$597.5B	$660.3B	$746.2B	$537.4B	$663.7B	$466.3B	$496.3B	$611.8B
Operating Income	$184.2B	$66.9B	-$74.9B	$184.6B	$69.0B	$194.1B	$47.5B	$201.4B
Operating Margin	15.7%	5.9%	-7.1%	16.7%	6.2%	16.0%	4.3%	16.5%
Interest Expense	$68.5B	$207M	$330M	$107.2B	$83.1B	$125.9B	$44.5B	$63.8B
Income Before Tax	$119.4B	$26.4B	-$107.3B	$150.6B	$28.2B	$136.3B	-$53.4B	$162.7B
Tax Expense	$27.3B	$2.6B	-$4.2B	$26.4B	$39.9B	$30.7B	-$28.7B	$49.5B
Net Income	$92.0B	$23.8B	-$103.2B	$124.2B	-$11.8B	$105.5B	-$24.8B	$113.2B
Net Margin	7.8%	2.1%	-9.8%	11.2%	-1.1%	8.7%	-2.2%	9.3%
EPS (Diluted)	$28.59	$7.51	$-32.62	$39.12	$-3.74	$32.92	$-7.92	$35.27
EBITDA	$380.3B	$193.0B	$181.3B	$439.4B	$316.5B	$456.2B	$157.9B	$337.5B
Shares Outstanding	3.22B	3.17B	3.16B	3.18B	3.15B	3.20B	3.12B	3.21B

TAK NYSE